{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-218026","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.595081+00:00","generated_at":"2026-06-24T00:54:30.843384+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"UroGen Q2 Jelmyto revenue $16.6M (+28% YoY); reaffirms FY22 guidance $70-80M","bullets":["Q2 Jelmyto net revenue $16.6M, up 22% QoQ and 28% YoY from $13.0M.","Net loss $26.7M ($1.18/share) vs $26.2M ($1.17/share) in Q2 2021.","Cash and marketable securities $112.4M as of June 30, 2022.","Reaffirms FY2022 Jelmyto revenue guidance of $70-80M; reduces operating expense forecast to $130-140M.","Enrollment in Phase 3 ENVISION trial for UGN-102 on track for completion by end of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-218026","json":"https://secwatch.observer/filing/0001193125-22-218026.json","markdown":"https://secwatch.observer/filing/0001193125-22-218026.md","text":"https://secwatch.observer/filing/0001193125-22-218026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312522218026/0001193125-22-218026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312522218026/d338870d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:54:30.843384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}